Sex Differences in Outcomes of Intravenous Thrombolysis in Acute Ischemic Stroke Patients with Preadmission Use of Antiplatelets.
Journal
CNS drugs
ISSN: 1179-1934
Titre abrégé: CNS Drugs
Pays: New Zealand
ID NLM: 9431220
Informations de publication
Date de publication:
04 2023
04 2023
Historique:
accepted:
28
02
2023
medline:
26
4
2023
pubmed:
29
3
2023
entrez:
28
3
2023
Statut:
ppublish
Résumé
To compare safety and functional outcomes of intravenous thrombolysis (IVT) between females and males with acute ischaemic stroke (AIS) in relation to preadmission use of antiplatelets. Multicentre cohort study of patients admitted from 1 January 2014 to 31 January 2020 to hospitals participating in the Swiss Stroke Registry, presenting with AIS and receiving IVT. Primary safety outcome was in-hospital symptomatic intracerebral haemorrhage (sICH). Primary functional outcome was functional independence at 3 months after discharge. Multivariable logistic regression models were fitted to assess the association between sex and each outcome according to preadmission use of antiplatelets. The study included 4996 patients (42.51 % females, older than males, median age 79 vs 71 years, p < 0.0001). Comparable proportions of females (39.92 %) and males (40.39 %) used antiplatelets before admission (p = 0.74). In total, 3.06 % females and 2.47 % males developed in-hospital sICH (p = 0.19), with similar odds (adjusted odds ratio, [AOR] 0.93, 95 % confidence interval, [CI] 0.63-1.39). No interaction was found between sex and preadmission use of either single or dual antiplatelets in relation to in-hospital sICH (p = 0.94 and p = 0.23). Males had higher odds of functional independence at 3 months (AOR 1.34, 95 % CI 1.09-1.65), regardless of preadmission use of antiplatelets (interaction between sex and preadmission use of either single or dual antiplatelets p = 0.41 and p = 0.58). No sex differences were observed in the safety of IVT regarding preadmission use of antiplatelets. Males showed more favourable 3-month functional independence than females; however, this sex difference was apparently not explained by a sex-specific mechanism related to preadmission use of antiplatelets.
Identifiants
pubmed: 36976463
doi: 10.1007/s40263-023-00997-7
pii: 10.1007/s40263-023-00997-7
pmc: PMC10126038
doi:
Substances chimiques
Fibrinolytic Agents
0
Tissue Plasminogen Activator
EC 3.4.21.68
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
351-361Informations de copyright
© 2023. The Author(s).
Références
Neurology. 2007 Mar 13;68(11):842-8
pubmed: 17353472
JAMA. 2006 Jan 18;295(3):306-13
pubmed: 16418466
Eur Stroke J. 2021 Mar;6(1):I-LXII
pubmed: 33817340
Thromb Haemost. 2010 Sep;104(3):471-84
pubmed: 20664898
Stroke. 2021 Jan;52(2):406-415
pubmed: 33493053
Neurology. 2019 Dec 10;93(24):e2170-e2180
pubmed: 31719135
Lancet. 2014 Nov 29;384(9958):1929-35
pubmed: 25106063
Front Neurol. 2020 Oct 08;11:545860
pubmed: 33133001
N Engl J Med. 1995 Dec 14;333(24):1581-7
pubmed: 7477192
Int J Stroke. 2015 Apr;10(3):317-23
pubmed: 25545076
Thromb Haemost. 1997 Apr;77(4):748-54
pubmed: 9134654
Stroke. 2013 Dec;44(12):3401-6
pubmed: 24172579
J Am Heart Assoc. 2016 May 20;5(5):
pubmed: 27207999
Neurology. 2020 Feb 18;94(7):e657-e666
pubmed: 31959709
Stroke. 2010 Feb;41(2):288-94
pubmed: 20056933
Ann Neurol. 2020 Oct;88(4):857-859
pubmed: 32686168
Lancet. 2007 Oct 20;370(9596):1453-7
pubmed: 18064739
Arch Neurol. 2008 May;65(5):607-11
pubmed: 18332238
Neurol Res Pract. 2020 Nov 20;2:40
pubmed: 33324940
Lancet. 2002 Jan 19;359(9302):189-98
pubmed: 11812552
Circ Cardiovasc Qual Outcomes. 2017 Feb;10(2):
pubmed: 28228454
JAMA Intern Med. 2020 Apr 1;180(4):574-583
pubmed: 32040165
Arch Neurol. 1989 Jun;46(6):660-2
pubmed: 2730378
Eur Heart J. 2014 Sep 1;35(33):2213-23b
pubmed: 25024407
Stroke. 2017 Jul;48(7):1877-1883
pubmed: 28619989
Lancet. 2020 Aug 22;396(10250):565-582
pubmed: 32828189
Eur J Neurol. 2016 Dec;23(12):1757-1762
pubmed: 27529662
Stroke. 2017 Mar;48(3):699-703
pubmed: 28143921
Ann Epidemiol. 2006 Feb;16(2):123-30
pubmed: 16246584
Lancet Neurol. 2006 Jul;5(7):603-12
pubmed: 16781990
Stroke. 2012 Apr;43(4):1171-8
pubmed: 22426314
Expert Rev Clin Pharmacol. 2014 Jul;7(4):469-85
pubmed: 24857340
J Am Coll Cardiol. 2012 Mar 6;59(10):891-900
pubmed: 22381424
Stroke. 2017 Jul;48(7):1720-1722
pubmed: 28619988
Int J Cardiol. 2019 Jul 1;286:198-207
pubmed: 30777407
Transl Stroke Res. 2018 Jun;9(3):267-273
pubmed: 29067622
Front Neurol. 2020 Jun 19;11:504
pubmed: 32636794
J Neurol. 2017 Jun;264(6):1227-1235
pubmed: 28550481
Nature. 1975 Jan 31;253(5490):355-7
pubmed: 1110780
Ann Neurol. 2018 Jul;84(1):89-97
pubmed: 30048012
Lancet Neurol. 2018 Jul;17(7):641-650
pubmed: 29914709
Stroke. 2009 Sep;40(9):3067-72
pubmed: 19608993
Stroke. 2017 Feb;48(2):367-374
pubmed: 28028149
JAMA Neurol. 2016 Jan;73(1):50-9
pubmed: 26551916